new molecules and indications for glp-1 medicines new molecules and indications for

The proportion achieving at least a 15% reduction in body weight ranged from 4.9% to 39.8% across the elecoglipron groups, whereas only 2.7% of placebo patients achieved a similar reduction

No one really around, Daniels said

Available data demonstrate meaningful efficacy with acceptable safety profiles in this specific population

Additionally, those with severe gastrointestinal disorders, such as gastroparesis, may not tolerate these medications well

Obesity in adolescents is associated with a wide range of metabolic and cardiovascular complications, including type 2 diabetes mellitus, hypertension, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and early manifestations of cardiovascular disease